BioCentury
ARTICLE | Clinical News

AC-201 CR: Interim Phase IIa data

January 11, 2016 8:00 AM UTC

Interim data from 36 gout patients in the first cohort of the double-blind, Taiwanese Phase IIa AC-201-GOU-002 trial showed that twice-daily oral AC-201 CR met the criteria of >=2 more responders, def...